Ipamorelin
Reported Onset
2–4 weeks
Primary Use
Selective GH release with a favorable safety profile and minimal side effects.
Dose
200mcg - 300mcg
Frequency
2-3x daily (ideally fasted or pre-sleep)
CJC-1295 (No DAC)
Reported Onset
2–4 weeks
Primary Use
Pulsatile GH release that mimics natural GH secretion patterns.
Dose
100mcg - 200mcg
Frequency
2-3x daily (with Ipamorelin)
Community Verdict
Often compared as a stack vs individual use — which alone is better? The community generally selects between Ipamorelin and CJC-1295 (No DAC) based on their specific goals and experience. Both compounds are available through physician-supervised protocols at Alukard, where a physician can help determine which is most appropriate for your situation.
Get a Physician-Supervised Protocol for Ipamorelin or CJC-1295 (No DAC) at Alukard
Community experiences are a starting point — but a physician-supervised protocol from Alukard gives you pharmaceutical-grade compounds, proper dosing, lab monitoring, and the safety of medical oversight.
MD
Supervised
GMP
Certified
Labs
Monitoring
COA
Verified